Biogen Seeks Dialogue With US CMS About Alzheimer's Drug Coverage Decision
Biogen's chief executive officer on Thursday said the company wants a dialogue with the CMS ahead of a final decision on coverage of its controversial Alzheimer's disease drug in April.
Reuters Health Information
source https://www.medscape.com/viewarticle/966555?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/966555?src=rss
Comments
Post a Comment